PO-0985: Hypofractionated radiotherapy with SIB in advanced incurable breast cancer-HYPORT B study

R. Santosham, Rania Mohammed Ahmed, Arabinda Das(NorthShore University HealthSystem), Sanjoy Chatterjee(Tata Medical Center), Santam Chakraborty(Tata Medical Center), A. Mahata(Tata Medical Center), S. Mandal(Bose Institute), A. Kumari, Shubhra Ray

Radiotherapy and Oncology

November 1, 2020

10.1016/s0167-8140(21)01003-3

Cited by 3

Related Papers

Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations

|South Asian Journal of Cancer|2017|48

HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis

|Radiotherapy and Oncology|2022|42

Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis

|Practical Radiation Oncology|2018|32

Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial

|Trials|2020|29

Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity

|European Journal of Cancer|2022|29